semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anesthesia Pain, Acute All patients over 18 yrs old  Cognitive decline, mental illness, drug addicts and non-Swedish speakers. Skin damage to fingers that make application more difficult. -
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Patients With Osteoarthritis Undergoing CAS-TKA primary and unilateral computer-assisted total knee arthroplasty  (1) patients who underwent bilateral TKAs, unicompartmental TKA or revision TKA (2) patients who had to remove previous implants or history of high-tibial or distal femoral corrective osteotomy (3) patients who were unable to response to the questionnaires
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bone Resorption Dental Diseases Patient aged ≥ 18 years old 2. Patient able to read, understand and give written consent to participate in the study 3. Patient affiliated with a social security system or beneficiary of such a system 4. Partially edentulous patient with 1 to 2 intercalary missing teeth or a terminal gap with distal vertical and lateral support bone volume 5. Presence of a bone deficit requiring horizontal and / or vertical bone augmentation (stage 4 or 5 of the Benic and Hammerle classification) treated by GBR for delayed placement of up to 4 dental implants 6. Possibility of acquisition by CBCT for the required protocol visits  General contraindication to bone graft and implant surgery 2. Pregnant woman or planned pregnancy during the study period or breast-feeding woman; 3. Patient who has had a bone augmentation by GBR during the previous 12 months, in the area targeted for filling with the allogeneic material 4. Patient who received less than 3 months ago a CBCT acquisition at the operative site 5. Patient simultaneously requiring more than one GBR augmentation in the same quadrant 6. Patient with signs of local infection at the targeted graft site 7. Systemic, metabolic or autoimmune disease that may adversely affect healing of soft and bone tissue (eg, unbalanced type 1 or type 2 diabetes) 8. Use of treatments (chemotherapy or radiotherapy) or drugs (bisphosphonates, chronic steroids) known to potentially interfere with tissue healing 9. Patient presenting a dental plaque objectified by an oral examination (Loe ≥ 2 on more than 50% of the dental surfaces) 10. Patient smoker of more than 10 cigarettes a day 11. Any other condition that, in the investigator's opinion, would be detrimental to the safety of the patient or fail to meet the requirements of the protocol
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Alveolar Osteitis Impacted Tooth Patients Age ≥ 18 years of age Willing and able to provide informed consent Ability to cooperate with the requirements of the study protocol Healthy patients without medical diseases or a history of bleeding problems Patients with the need of extraction of third molars The third molars had to be symmetrical, partially-erupted and in the Class I, Level B according to Pell & Gregory classification and in the vertical angulations according to Winter's classification  Patients who have pre-existing abscess or cellulitis, acute pericoronitis, or pre-existing conditions such as an odontogenic cyst or tumour associated with their third molars Patients who were pregnant and breastfeeding Patients with drug usage such as bisphosphonate, steroids and antidepressants Patients who had a smoking habit
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 70.0-999.0,  Patients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry Mouth ≥ 70 years of age Clinical diagnosis of chronic dry mouth defined as a Numeric Rating Scale (NRS) score ≥ 5 (scale 0 with 0 = no dry mouth and 10= worst possible dry mouth) on severity of xerostomia for more than 3 months  Existence of cognitive impairment and/or diagnosis of dementia appraised by treating physician Inability to fill out the questionnaires due to other reasons Prior radiation therapy of the head-and-neck region Known m. Sjögren disease Contra-indications for parasympathicomimetics (uncontrolled asthma, acute heart failure, active peptic ulceration, known hypersensitivity to pilocarpine, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle closure) glaucoma
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 10.0-16.0,  Scoliosis Idiopathic Scoliosis; Adolescence Patients with scoliosis diagnosed and followed up by the attending physician 16 age group Patients who voluntarily agreed to participate in the study Living in Antalya/TURKEY  Mental retardation, congenital scoliosis or spinal deformity, spinal surgery, neuromuscular disease, rheumatologic disease, tumor, cardiovascular or pulmonary disease, vertigo attack or balance problem, neurological disease İndividual who does not sign the consent form
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Achilles Tendinopathy Men and non-pregnant women aged 18-60 years Patients suffering from a gradually evolving painful condition in the Achilles tendon located at the midportion for at least 12 weeks (Diagnosis based on clinical examination showing a painful thickening of the Achilles tendon located at a level of 2 to 6cm above the tendon insertion, and confirmed by ultrasonography: local thickening of the tendon, irregular tendon structure with hypoechoic areas and irregular fiber orientation) VISA-A score less than 65 at baseline Be informed of the nature of the study and provide written informed consent  Clinical suspicion of insertional disorders (pain at the site of the insertion of the Achilles tendon on the calcaneum) Concomitant or previous participation in a clinical investigation within the last 3 months (wash out) prior to study Clinical suspicion of an Achilles tendon rupture Suspicion of internal disorders: spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis Severe foot deformity Condition that prevents the patients from executing an active exercise program Pregnant or lactating females History of treatment with corticosteroids, estrogens, long term quinolone antibiotics, and cholesterol drugs Persons with electronic implants (e.g. pacemaker, cochlear implants, drug pump, deep brain stimulator, etc.) Patients with organ transplants
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hypophosphatasia HPP (CASES) Clinical diagnosis of HPP (with or without previous genetic test confirmation) Evidence of burden of disease (HPP) including abnormal gait, muscle weakness, pain, recurring fractures, slow healing fractures and/or bone deformities Age ≥ 18 years Able and willing to participate in the study Able to give written informed consent (CONTROLS) Healthy men and women with normal bone mineral density (defined as a DXA bone mineral density T score at the lumbar spine or total hip greater than -1) Age ≥ 18 years Able and willing to participate in the study  HPP (CASES) Individuals with BMI<18, or BMI>30 kg/m2 Other conditions known to affect serum ALP and PLP Coeliac disease, B12 deficiency, untreated hypothyroidism, Wilson's disease Taking nutritional supplements containing vitamin B6 within past two weeks History of, or current: Severe ischaemic heart disease, rheumatoid arthritis, ankylosing spondylitis, cancer (concurrent) History of, or current neurological diseases affecting the neuromuscular system including Parkinson's disease, CVA, muscular dystrophy, myasthenia, cerebral trauma, peripheral neuropathy Treatment for more than 3 months in a year or under treatment with oral corticosteroids History of any long term immobilization (duration greater than three months) Conditions or surgery which prevent the acquisition or analysis of musculoskeletal images
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 13.0-60.0,  Psoriasis minimum age 13 years maximum age 60 years both males and females affected with mild, moderate and severe psoriasis  hypertension cardiovascular disorders pregnancy lactation renal failure liver failure hypersensitivity to drug
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  X-linked Hypophosphatemia Hereditary Hypophosphatemia Understand oral and written Danish Able to consent For XLH only: 1. genetically verified XLH by detection of a disease-causing mutation in PHEX or a positive family history of X-linked hypophosphatemia. 2. biochemically verified hereditary hypophosphatemia: serum PO4 below normal range and low TmPO4/GFR, and/or elevated serum FGF23 and a history of childhood rickets or spontaneous endodontic abscesses to acquired hypophosphatemia, e.g., tumor-induced osteomalacia  P-25OHD < 25 mmol/L* Severe co-morbidities, which in the opinion of the investigator may have major impact on study outcomes. This may but is not limited to o poorly controlled hyperthyroidism o Paget disease o type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus o severe and chronic cardiac, liver, or renal disease o Cushing syndrome o Rheumatoid arthritis o Active pancreatitis o Malnutrition o Recent prolonged immobility* o Active malignancy (including myeloma) Treatment with o Burosumab Beta-blockers Oral steroids For controls only disturbances in the calcium or phosphate homeostasis participants with low 25OHD levels or recent immobility may be re-screened for participations 6 months after this has been corrected
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dental Implant Failed Periodontally healthy remaining dentition or presenting with mild gingivitis with adequate oral hygiene Presence of a partially edentulous alveolar ridge that is planned to be restored with no more than 2 implants To have 1 or 2 implants restored with a crown or fixed bridge Presence of a non-infected site Presence of enough bone and soft tissue for the implant to be placed without additional bone augmentation in a 1-stage approach (with healing abutment) Implants 6 mm long or longer Subjects able and willing to provide written informed consent and comply with study procedures  Subjects taking regular analgesics or antidepressants Smoking 10 cigarettes/cigars or more per day Marijuana smokers Use of vaping devices or e-cigarettes Drug abuse Completely edentulous individuals Pregnant and nursing women Allergies to macrolides, and/or non-steroidal anti-inflammatory analgesics Active peptic ulcers or susceptibility to peptic ulcers Any systemic or local immunodeficiency
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-22.0,  Acute Myeloid Leukemia All patients must be enrolled on APEC14B1 and consented to Screening (Part A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens must be done according to the Manual of Procedures). Risk stratification will not be possible without the submission of viable samples. Given there are multiple required samples, bone marrow acquisition techniques such as frequent repositioning or performing bilateral bone marrow testing should be considered to avoid insufficient material for required studies. Consider a repeat marrow prior to starting treatment if there is insufficient diagnostic material for the required studies Patients must be less than 22 years of age at the time of study enrollment Patient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease Patient must have 1 of the following >= 20% bone marrow blasts (obtained within 14 days prior to enrollment) In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy < 20% bone marrow blasts with one or more of the genetic abnormalities (sample obtained within 14 days prior to enrollment) A complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment) ARM C: Patient must be >= 2 years of age at the time of Late Callback ARM C: Patient must have FLT3/ITD allelic ratio > 0.1 as reported by Molecular Oncology  Patients with myeloid neoplasms with germline predisposition are not eligible Fanconi anemia Shwachman Diamond syndrome Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Any other known bone marrow failure syndrome Any concurrent malignancy Juvenile myelomonocytic leukemia (JMML) Philadelphia chromosome positive AML Mixed phenotype acute leukemia Acute promyelocytic leukemia